Physician profile
Victor Gall
NPI 1508158627
$597.88
in general payments reported to CMS, 2019-2025
17 companies · $60.90 in 2025
The $60.90 reported for 2025 was less than what a typical Surgical Oncology provider received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.93 · 2022: $55.25 · 2023: $165 · 2024: $301 · 2025: $60.90.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $528.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $527.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dilon Technologies, INC. | $139.10 | 2024 | Hemoblast Bellows |
| Myriad Genetic Laboratories, INC. | $108.72 | 2023 | Myrisk |
| Baxter Healthcare | $45.12 | 2021-2024 | Floseal |
| Pharmacosmos Therapeutics INC. | $38.33 | 2024 | Cosela, Monoferric |
| Acera Surgical, INC. | $31.63 | 2025 | Restrata Wound Matrix |
| Bayer Healthcare Pharmaceuticals INC. | $29.27 | 2025 | |
| Integra Lifesciences Corporation | $24.36 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.22 | 2024 | Fruzaqla |
| Array Biopharma INC | $20.34 | 2024 | Tukysa, Braftovi, Mektovi |
| Pfizer INC. | $20.16 | 2023 | |
| Medtronic, INC. | $19.61 | 2023 | Gi Genius |
| Astrazeneca Pharmaceuticals LP | $18.69 | 2024 | Calquence |
| Davol INC. | $16.94 | 2022 | |
| Incyte Corporation | $16.88 | 2023 | Jakafi |
| Pharmaessentia USA Corporation | $16.21 | 2024 | Besremi |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $15.35 | 2024 | Keytruda |
| Innocoll Pharmaceuticals Limited | $13.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victor Gall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.